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Abstract
Background: Glucocorticoids have an important role in early growth and development. Glucocorticoid receptor
gene polymorphisms have been identified that contribute to the variability in glucocorticoid sensitivity. We
examined whether these glucocorticoid receptor gene polymorphisms are associated with growth in fetal and
early postnatal life.
Methods: This study was embedded in a population-based prospective cohort study from fetal life onwards. The
studied glucocorticoid receptor gene polymorphisms included BclI (rs41423247), TthIIII (rs10052957), GR-9b (rs6198),
N363S (rs6195) and R23K (rs6789 and6190). Fetal growth was assessed by ultrasounds in second and third trimester
of pregnancy. Anthropometric measurements in early childhood were performed at birth and at the ages of 6, 14
and 24 months postnatally. Analyses focused on weight, length and head circumference. Analyses were based on
2,414 healthy, Caucasian children.
Results: Glucocorticoid receptor gene polymorphisms were not associated with fetal weight, birth weight and
early postnatal weight. Also, no associations were found with length and head circumference. Neither were these
polymorphisms associated with the risks of low birth weight or growth acceleration from birth to 24 months of
age.
Conclusions: We found in a large population-based cohort no evidence for an effect of known glucocorticoid
receptor gene polymorphisms on fetal and early postnatal growth characteristics. Further systematic searches for
common genetic variants by means of genome-wide association studies will enable us to obtain a more complete
understanding of what genes and polymorphisms are involved in growth in fetal life and infancy.
Background
Glucocorticoids are important regulators of growth,
development and metabolism. The effects of these hor-
mones, including cortisol, are mediated by glucocorti-
coid receptors. The sensitivity to glucocorticoids is
known to show a large interindividual variation [1].
Polymorphisms in the glucocorticoid receptor gene have
been suggested to contribute to this difference in sensi-
tivity and thereby to differences in growth, development
and metabolism. These glucocorticoid receptor gene
variants may also explain part of the previously
demonstrated associations between growth characteris-
tics in early life and metabolic disease, including type
2 diabetes, in adult life [2,3].
Four different variants in the glucocorticoid receptor
gene have been described to be associated with cortisol
sensitivity [4-6]. Several studies analyzed the associations
of these glucocorticoid receptor gene variants with body
composition and obesity in adults. The R23K variant
(two Single Nucleotide Polymorphisms in complete link-
age disequilibrium) was found to be associated with
higher serum cortisol concentrations as well as a smaller
decrease in cortisol after dexamethasone suppression
tests. Furthermore, carriers showed lower fasting insulin
levels and lower LDL cholesterol levels. These data
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suggest that carriers of the 23K variant of the R23K
polymorphism are relatively more cortisol resistant than
non-carriers, which results in a better metabolic health
profile in adults [7,8]. By contrast, the Bcl1 and N363S
polymorphisms were found to cause the opposite effects
[9-11]. In healthy subjects over 55 years, these poly-
morphisms were associated with hypersensitivity to glu-
cocorticoids, resulting in an increased body mass index
(BMI) [10]. In addition, a large meta-analysis performed
in almost 6,000 individuals concluded that there is no
compelling evidence that the N363 polymorphism of the
GR-gene is associated with either average BMI or obe-
sity risk [12]. However, results were not consistent
[13,14]. The TthIIII polymorphism was associated with
elevated diurnal cortisol levels, but not with any anthro-
pometric or glucose related phenotype [15]. Recently,
the GR-9b polymorphism was found to be related to a
decreased sensitivity to glucocorticoids, leading to an
increased risk of cardiovascular disease [16]. These
results suggest that common functional variants of the
glucocorticoid receptor gene may affect body composi-
tion. However, apart from the R23K variant, the exact
mechanisms have not been confirmed. Also, thus far no
studies did assess the effects of these glucocorticoid
receptor gene polymorphisms in young children. How-
ever, although some studies showed an increasing effect
of genetic variants in the glucocorticoid receptor gene
with advancing age [8,17], the effect of these glucocorti-
coid receptor gene polymorphisms might be stronger on
anthropometric measures in early life than on body
mass index in adult life, because of very limited life style
influences.
We hypothesised that genetic variants leading to
increased glucocorticoid sensitivity are associated with
fetal growth retardation and postnatal growth accelera-
tion. This would be in line with well-known associations
of high cortisol exposures with low birth weight and
higher postnatal weight. Therefore, we studied in a
population-based prospective cohort study from fetal
life until the age of 2 years the effects of the BclI,
TthIIII, GR-9b, N363S and R23K polymorphisms on
anthropometrics in second and third trimester of
pregnancy, at birth and postnatally until the age of
24 months.
Methods
Design
This study was embedded in the Generation R Study, a
prospective cohort study from early fetal life onwards.
This study is designed to identify early environmental
and genetic determinants of growth, development and
health from fetal life until young adulthood and has
been described previously in detail [18,19]. Fetal and
postnatal growth and their main determinants were
repeatedly measured by physical examinations, fetal
ultrasounds and questionnaires. We have previously
shown that of all eligible children born in the study area
61% participated in the study [19]. The study has been
approved by the Medical Ethics Committee of the Eras-
mus Medical Center, Rotterdam. Written informed con-
sent was obtained from all parents.
Population for analysis
Analysis were restricted to Caucasian children (n =
4,527) and of whom DNA was available for genotyping
(n = 2,839). Reasons for non-availability of DNA were
mainly due to logistical constraints at birth, including a
relatively large number of home deliveries in the Neth-
erlands and time constraints during hospital deliveries.
Fetal growth measurements were available in 2,746 and
2,791 children in second and third trimester of preg-
nancy, respectively. A total of 81% (n = 2,274), 75% (n =
2,136) and 68% (n = 1,929) participated in the postnatal
assessments at the ages of 6, 14 and 24 months. Infor-
mation about anthropometrics of at least one of the
postnatal visits was available in 2,414 subjects of whom
72%, 91% and 100% had measurements at least three,
two and one visit. In total, analyses were based on more
than 6,000 measurements.
Genotyping
DNA was collected from cord blood samples at birth.
All participants were genotyped for five known gluco-
corticoid receptor gene polymorphisms which are
known to be associated with changes in glucocorticoid
sensitivity or diurnal cortisol levels: BclI (rs41423247),
TthIIII (rs10052957), GR-9b (rs6198), N363S (rs6195)
and R23K (rs6189 and 6190) [4,5]. The five SNPs used
in this study were chosen on the basis of their reported
functionality, and not as tagging SNPs, and the purpose
was not to determine the level of variation in the GR
gene. However, we used four of these five SNPs as tag-
ging SNPs for the GR gene in the program HaploView.
The program showed that these four SNPs identify one
third (19 out of 57) haplotypes. Only four SNPs could
be analysed this way because the fifth (rs41423257),
coincidentally the SNP with the highest minor allele fre-
quency, is not in the HapMap database. This result sug-
gests that a considerable part of the genetic variation in
the GR gene is captured by these five SNPs. The SNPs
used here are all within one LD-block [20]. This block
also includes the (proximal) promoters and exon 1 var-
iants 1D, 1E, 1B, 1F, 1C and 1H. It also includes the GR
CpG island. The only exon 1 variant not included is 1A.
The majority of transcripts contain either 1C or 1B.
Figure 1 schematically shows the specific nucleotide var-
iations and allele frequencies of these polymorphisms.
Genotyping of the five glucocorticoid receptor gene
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polymorphisms was performed using Taqman allelic dis-
crimination assay (Applied Biosystems, Foster City, CA)
and Abgene QPCR ROX mix (Abgene, Hamburg Ger-
many). The genotyping reaction was amplified using the
GeneAmp® PCR system 9600 (95°C (15 minutes), then
40 cycles of 94°C (15 seconds) and 60°C (1 minute)).
The fluorescence was detected on the 7900HT Fast
Real-Time PCR System (Applied Biosystems) and indivi-
dual genotypes were determined using SDS software
(version 2.3, Applied Biosystems). Genotyping was suc-
cessful in 97-99% of the samples for the five genotypes.
To confirm the accuracy of the genotyping results 276
randomly selected samples were genotyped for a second
time with the same method. The error rate was less
than 1% for all genotypes. We used the genotype data
for each of the 5 polymorphisms to infer the haplotypes
present in the population using the program PHASE,
which implements a Bayesian statistical method for
reconstructing haplotypes from population genotype
data [21]. Instead of individual polymorphisms, we stu-
died the haplotype structure of the glucocorticoid recep-
tor gene to encompass a major proportion of variation
in the gene. We excluded very rare polymorphisms
because they have potential to explain only a very small
fraction of variation in response to glucocorticoids seen
between individuals. For each haplotype, 3 genotype
combinations were distinguished as carrying 0, 1, or 2
copies of the haplotype allele. Haplotype 1 carries the
major alleles of the polymorphisms; therefore, the refer-
ence allele is defined as carrying 2 copies of haplotype
1. Genotype and allele frequencies were in Hardy Wein-
berg equilibrium (p > 0.01).
Growth measurements
Fetal growth characteristics
Fetal ultrasound examinations were carried out during
visits at the research centers. The respective median
(95% range) gestational ages for these visits were 12.6
weeks (9.6 - 16.9), 20.4 weeks (18.6 - 22.5) and 30.2
weeks (28.5 - 32.5). The second and third visits were
considered as second and third trimester measurements.
These fetal ultrasounds were used both to establish
gestational age (first ultrasound) and to assess fetal
growth characteristics [22]. Fetal growth measurements
used for the present study comprised head circumfer-
ence (HC), abdominal circumference (AC) and femur
length (FL) in the second and third trimester measured
to the nearest millimeter using standardized ultrasound
procedures [23-25]. Estimated fetal weight was calcu-
lated using the formula by Hadlock using head circum-
ference, abdominal circumference and femur length:
EFW (cm) = 10^(circ;1.326 - 0.00326*AC*FL +
0.0107*HC + 0.0438*AC + 0.158*FL) [26]. Growth mea-
surements in early pregnancy (gestational age < 18
weeks) were not included, since these fetal ultrasound
examinations were performed primarily to establish
gestational age. Gestational age-adjusted standard devia-
tion scores were constructed for these fetal growth
measurements.
Postnatal growth characteristics
Birth weight, date of birth and gender were obtained
from community midwife and hospital registries. Well-
trained staff in community health centers obtained post-
natal growth characteristics using standardized proce-
dures. Based on the routine health care program, visits
for these growth characteristics were grouped into three
age periods: 6 (range 5 - 8.99) months; 14 (range 12 -
18.38) months and 24 (range 23 - 28.93) months.
Anthropometrics were measured without clothes.
Weight was measured to the nearest gram using electro-
nic scales. Length was measured to the nearest milli-
meter in the supine position using a neonatometer at
the ages of 6 and 14 months, and height was measured
in the upright position at the age of 24 months. Head
Figure 1 Schematic overview of the glucocorticoid receptor gene polymorphisms and haplotypes. Haplotypes are numbered in order of
decreasing frequency. The nucleic acid changes are indicated; C = Cytidine, G = Guanine, A = Adenosine, T = Thymine.
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circumference was postnatally measured at the age of 6
and 14 months.
Data analysis
Differences in baseline characteristics between boys and
girls were examined by independent samples t-tests
(continuous variables) or Pearson’s chi-square (categori-
cal variables). Because of the low number of homozy-
gous subjects for haplotype 5 (n = 8) and 6 (n = 1),
these haplotypes were analyzed as carriers (1 or 2
copies) and non-carriers (0 copies).
We used an additive model to study the effects of the
different haplotypes on pre- and postnatal growth The
associations of the glucocorticoid receptor haplotypes
with pre- and postnatal growth characteristics (weight,
length and head circumference) were analyzed in three
different time-intervals: from second trimester to birth,
from birth to 24 months of age and from second trime-
ster to 24 months of age. Since, no data were available
for head circumference at 24 months of age, head cir-
cumference was analyzed until the age of 14 months.
With these outcomes, the effects of glucocorticoid
receptor polymorphisms on skeletal and non-skeletal
growth and head circumference can be studied. We
used femur length as measure of skeletal growth in fetal
life (correlation femur length in third trimester of
pregnancy and length at 1 month of age: r = 0.30, p-
value < 0.001). To assess longitudinally measured
growth patterns from fetal life to infancy, we performed
repeated measures regression analysis. This regression
technique takes the correlation of multiple measure-
ments within one subject into account, assesses both the
time-independent and time-dependent effect of the glu-
cocorticoid receptor genotypes, and allows for incom-
plete outcome data [27,28]. Haplotype and its
interaction with age were included in these models. To
account for age variation between individuals within
each time interval, these analyses were conducted using
Table 1 Distribution of the different haplotype alleles of
the glucocorticoid receptor gene within our study
population (n = 2,414)
Glucocorticoid receptor haplotype (copies) N (%)
Haplotype 1
0 531 (22.0)
1 1,379 (57.1)
2 504 (20.9)
Haplotype 2
0 1,265 (52.4)
1 1,017 (42.1)
2 132 (5.5)
Haplotype 3
0 1,668 (69.1)
1 699 (29.0)
2 47 (1.9)
Haplotype 4
0 1,688 (70.0)
1 677 (28.0)
2 49 (2.0)
Haplotype 5
0 2,196 (91.0)
1 or 2 218 (9.0)
Haplotype 6
0 2,242 (92.9)
1 or 2 172 (7.1)
Values are number of persons (%).
Table 2 Fetal and infant characteristics (n = 2,414)
Boys
(n = 1,233)
Girls
(n = 1,181)
P-value
Second trimester
Gestational age (weeks) 20.6 (18.7 - 23.3) 20.4 (18.5 - 23.1) <0.01
Estimated fetal weight
(grams)
386 (91) 374 (86) <0.01
Femur length (mm) 33.3 (3.2) 33.2 (3.3) 0.55
Head circumference (mm) 181.0 (13.1) 177.2 (13.0) <0.01
Third trimester
Gestational age (weeks) 30.4 (28.6 - 33.0) 30.3 (28.3 - 32.8) <0.01
Estimated fetal weight
(grams)
1646 (258) 1620 (268) <0.01
Femur length (mm) 57.4 (2.9) 57.4 (2.9) 0.64
Head circumference (mm) 288.8 (11.8) 283.7 (11.2) <0.01
Birth
Gestational age 40.1 (35.0 - 42.4) 40.1 (35.2 - 42.1) 0.42
Weight (grams) 3518 (596) 3400 (574) <0.01
Length (cm)* 55.1 (2.4) 54.0 (2.1) <0.01
Head circumference)* 38.1 (1.3) 37.3 (1.2) <0.01
Weight < 2500 grams (%) 29 (2.4) 26 (2.2) 0.80
Preterm birth
(<36 weeks) (%)
41 (3.3) 37 (3.1) 0.79
Age 6 months
Age at visit (months) 6.2 (5.2 - 7.9) 6.2 (5.2 - 7.9) 0.28
Weight (grams) 8,078 (845) 7,540 (812) <0.01
Length (cm) 68.5 (2.4) 66.8 (2.3) <0.01
Head circumference (cm) 44.2 (1.3) 43.1 (1.7) <0.01
Age 14 months
Age at visit (months) 14.3 (13.6 - 16.2) 14.3 (13.4 - 16.0) 0.05
Weight (grams) 10,824 (1,070) 10,191 (1,018) <0.01
Length (cm) 78.9 (2.6) 77.5 (2.6) <0.01
Head circumference (cm) 47.7 (1.3) 46.6 (1.1) <0.01
Age 24 months
Age at visit (months) 24.8 (23.4 - 28.1) 24.8 (23.4 - 28.1) 0.48
Weight (grams) 13,140 (1,376) 12,651 (1,412) <0.01
Length (cm) 88.9 (3.4) 87.7 (3.4) <0.01
Values are means (SDS) or medians (95% range).
Differences between boys and girls were compared using independent
samples t-tests.
*Measured at 1 months of age
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age-adjusted standard deviation scores as outcomes. The
models can be written as:
Weight SDS    age   glucocorticoid receptor ha1 2      0 * * plotype 
 glucocorticoid receptor haplotype age3  * * .
Similar models were used for length and head circum-
ference growth. The term including ‘b0’ reflects the
intercept and the term including ‘b1’ reflects the growth
per week for the reference group. The terms including
‘b2’ and ‘b3’ reflect the age independent and dependent
growth differences between the different categories of
the glucocorticoid receptor genotype, respectively[28].
All betas, including the intercept and age interactions,
were included as random effects in the models. To
study the dominant effects of the glucocorticoid recep-
tor gene polymorphisms, we merged the group hetero-
zygous and homozygous variant subjects and performed
the same analyses. In addition, we performed all these
analyses stratified for birth weight.
Furthermore, we fitted multiple logistic regression
models to analyze the associations of the different gluco-
corticoid receptor haplotypes with prenatal growth
retardation (growth deceleration) and postnatal growth
acceleration. We defined growth deceleration as a
decrease in weight SDS from second trimester of preg-
nancy until birth of >-0.67 standard deviation and growth
acceleration as an increase in weight SDS from birth to
24 months of age of more than 0.67 standard deviation
[29]. Each anthropometric outcome was analyzed using
gender and age adjusted standard deviation scores (SDS).
These were based on reference growth curves from the
whole study population. Age at visit and gender were
included in these models as confounding variables, since
they changed the effects estimates of interest on pre- and
postnatal growth substantially (>10%).
With a sample size of 2,400 subjects and assuming a
statistical power level (1 - b) of 0.80 and a level of sig-
nificance (a) of 0.05, we were able to detect differences
in growth characteristics of about 0.42 SD and 0.19 SD
for exposure rates of 2% and 10%, respectively. These
differences correspond with 246 and 112 grams in birth
weight. Similarly we were able detect Odds ratios (OR)
of 2.51 and 1.57 for exposure rates of 2% and 10%,
respectively. All effect estimates are presented with their
Table 3 Associations of glucocorticoid receptor haplotype with repeatedly measured weight from mid-pregnancy until
24 months of age
Weight SDS change
2nd trimester - birth
(95% CI)
Weight SDS change
Birth - 24 months
(95% CI)
Weight SDS change
2nd trimester - 24 months
(95% CI)
Glucocorticoid receptor haplotype (copies)
Haplotype 1
0 0.03 (-0.06, 0.12) -0.02 (-0.12, 0.08) 0.05 (-0.05, 0.15)
1 0.02 (-0.05, 0.09) -0.03 (-0.11, 0.05) 0.03 (-0.04, 0.11)
2 Reference Reference Reference
Haplotype 2
0 Reference Reference Reference
1 -0.06 (-0.12, 0.01) -0.02 (-0.09, 0.06) -0.10 (-0.17, -0.03)*
2 -0.01 (-0.15, 0.13) -0.01 (-0.17, 0.16) -0.02 (-0.18, 0.15)
Haplotype 3
0 Reference Reference Reference
1 0.06 (-0.01, 0.14) 0.06 (-0.02, 0.14) 0.09 (0.01, 0.17)*
2 0.02 (-0.21, 0.25) 0.02 (-0.26, 0.29) 0.14(-0.14, 0.42)
Haplotype 4
0 Reference Reference Reference
1 -0.02 (-0.09, 0.05) 0.02 (-0.07, 0.10) 0.12 (-0.15, 0.40)
2 -0.21 (-0.43, 0.02) 0.07 (-0.21, 0.36) 0.16 (-0.10, 0.44)
Haplotype 5
0 Reference Reference Reference
1 or 2 -0.01 (-0.18, 0.16) -0.36 (-1.02, 0.29) -0.16 (-0.75, 0.43)
Haplotype 6
0 Reference Reference Reference
1 or 2 -0.20 (-0.41, 0.01) 0.97 (-0.99, 2.93) 0.54 (0.13, 0.96)*
Values are regression coefficients (95% confidence interval) and reflect the difference in standard deviation score of weight from 2nd trimester until 24 months of
age for the different glucocorticoid haplotypes. SDS, gestational age adjusted standard deviation score; CI, confidence interval. Models are adjusted for age at
visit and gender.
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95% confidence interval (95% CI). Statistical analyses
were performed using the Statistical Package of Social
Sciences version 15.0 for Windows (SPSS Inc, Chicago,
IL, USA) and the Statistical Analysis System (SAS) for
Windows, version 9.1.3.
Results
The distribution of the different glucocorticoid receptor
haplotypes within our study population is presented in
Table 1. Haplotype 1, 2, 3 and 4 were most frequent
with allele frequencies of 42.4%, 22.7%, 14.3% and
13.4%, respectively. Haplotypes 5 and 6 had allele fre-
quencies of 4.1% and 3.1%, respectively. Comparison of
means of baseline characteristics between carriers of 0,
1 or 2 copies of haplotype 1 to 6 revealed no significant
differences for the covariates age at visit and gender.
Table 2 presents the baseline characteristics of infants
who participated in the postnatal visits. There was a
slight male preponderance (51%) in our study popula-
tion. The overall median ages (95% range) in infants at
their visits were 6.2 months (5.2 - 7.9), 14.3 months
(13.5 - 16.1) and 24.8 months (23.4 - 28.1).
Table 3 shows the associations of glucocorticoid
receptor haplotypes with pre- and postnatal weight until
the age of 24 months. No consistent associations were
found between the different haplotypes and repeatedly
measured weight in the three different time-intervals.
Also, no consistent associations were found with length
and head circumference (Table 4 and 5). In the domi-
nant models, the associations between the glucocorticoid
receptor gene polymorphisms were also not significant.
A stratified analysis among low birth weight children,
focused on the associations of the haplotypes with fetal
and early postnatal growth characteristics did not show
any significant results (data not shown).
Associations of the different haplotypes with the risks
of prenatal growth retardation (growth deceleration) and
postnatal growth acceleration are presented in Table 6.
No significant differences were found in risks of prenatal
growth deceleration and postnatal growth acceleration
for the different haplotypes. However, children who
showed prenatally an increased risk of growth retardation
compared to the reference, tend to have an increased risk
of growth acceleration in postnatal life as well.
Table 4 Associations of glucocorticoid receptor haplotype with repeatedly measured length from mid-pregnancy until
24 months of age
Length SDS change
2nd trimester - birth
(95% CI)
Length SDS change
Birth - 24 months
(95% CI)
Length SDS change
2nd trimester - 24 months
(95% CI)
Glucocorticoid receptor haplotype (copies)
Haplotype 1
0 0.01 (-0.09, 0.10 -0.01 (-0.13, 0.12) 0.01 (-0.09, 0.10)
1 0.02 (-0.05, 0.09) -0.01 (-0.10, 0.09) 0.01 (-0.07, 0.08)
2 Reference Reference Reference
Haplotype 2
0 Reference Reference Reference
1 0.02 (-0.08, 0.12) 0.02 (-0.07, 0.11) -0.07 (-0.14, 0.01)
2 0.08 (-0.08, 0.24) 0.03 (-0.19, 0.26) 0.10 (-0.06, 0.26)
Haplotype 3
0 Reference Reference Reference
1 0.09 (0.02, 0.16)* 0.05 (-0.05, 0.15) 0.07 (-0.01, 0.14)
2 0.16 (-0.08, 0.40) 0.13 (-0.24, 0.50) 0.12 (-0.15, 0.38)
Haplotype 4
0 Reference Reference Reference
1 -0.03 (-0.10, 0.05) -0.07 (-0.17, 0.04) -0.02 (-0.10, 0.06)
2 -0.23 (-0.47, 0.01) -0.02 (-0.40, 0.34) -0.15 (-0.42, 0.11)
Haplotype 5
0 Reference Reference Reference
1 or 2 0.14 (0.02, 0.25)* 0.02 (-0.14, 0.19) 0.18 (0.05, 0.30)†
Haplotype 6
0 Reference Reference Reference
1 or 2 -0.10 (-0.23, 0.03) -0.05 (-0.23, 0.14) -0.11 (-0.25, 0.03)
Values are regression coefficients (95% confidence interval) and reflect the difference in standard deviation score of length from 2nd trimester until 24 months of
age for the different glucocorticoid haplotypes. SDS, gestational age adjusted standard deviation score; CI, confidence interval. Models are adjusted for age at
visit and gender.
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Discussion
In our population-based prospective cohort study we
showed that glucocorticoid receptor gene polymorph-
isms are not consistently associated with growth in fetal
and early postnatal life. Furthermore, we demonstrated
that these polymorphisms were not related to size at
birth or growth acceleration during the first 2 years of
life.
The major strengths of our study are its prospective
design from early fetal life and the size of the popula-
tion-based cohort. Our analyses were based on over
6,000 growth measurements. Furthermore, the relative
effect of variants of the glucocorticoid receptor gene on
growth measurements might be larger in childhood,
when the effect of various environmental factors, such
as life style habits, is limited. Although, there are also
studies that indicate that small differences between indi-
viduals may increase with advancing age [8,17]. In sub-
jects who were born very preterm and followed up until
the age of 19 years, the 23 K variant in the GR gene was
associated with lower fasting insulin levels and a lower
HOMA-IR as well as with a taller stature departing
from the age of 1 year. Furthermore, these children
showed complete catch-up growth between the ages of
3 months and 1 year. Apparently, the nature of the
population studied also plays a role. A possible limita-
tion is that the current study was performed in a rela-
tively healthy cohort, resulting in a relatively small
number of low birth weight children (n = 55). A strati-
fied analysis among these children, focused on the asso-
ciations of the haplotypes with fetal and early postnatal
growth characteristics did not show any significant
resuls. Larger studies among low birth weight children
might be able to identify specific effects of haplotypes
on early growth characteristics. DNA for genotyping
was available in 59% of all subjects and was isolated
from cord-blood. Missing cord-blood was mainly caused
by logistical restraints at delivery. Of all genotyped eligi-
ble subjects at baseline, 22% did not participate in fol-
low-up measurements. Our study was designed to assess
pre- and postnatal growth in a relatively healthy group
of children. As a consequence, the group of children
Table 5 Associations of glucocorticoid receptor haplotype with repeatedly measured head circumference from mid-
pregnancy until 14 months of age
Head circumference SDS
change
2nd trimester - birth
(95% CI)
Head circumference SDS
change
Birth - 14 months
(95% CI)
Head circumference SDS
change
2nd trimester - 14 months
(95% CI)
Glucocorticoid receptor haplotype
(copies)
Haplotype 1
0 -0.10 (-0.20, 0.01) -0.16 (-0.33, 0.01) -0.09 (-0.18, 0.01)
1 -0.05 (-0.13, 0.03) -0.11 (-0.24, 0.02) -0.06 (-0.13, 0.01)
2 Reference Reference Reference
Haplotype 2
0 Reference Reference Reference
1 -0.07 (-0.16, 0.01) 0.01 (-0.11, 0.12) -0.05 (-0.12, 0.02)
2 -0.12 (-0.30, 0.06) 0.08 (-0.18, 0.35) -0.02 (-0.17, 0.13)
Haplotype 3
0 Reference Reference Reference
1 0.11 (0.03, 0.20)* 0.12 (-0.01, 0.25) 0.10 (0.02, 0.17)†
2 0.11 (-0.17, 0.40) -0.12 (-0.53, 0.29) 0.08 (-0.16, 0.33)
Haplotype 4
0 Reference Reference Reference
1 0.01 (-0.07, 0.10) 0.08 (-0.05, 0.21) 0.12 (-0.15, 0.40)
2 0.18 (-0.12, 0.47) 0.19 (-0.22, 0.60) 0.17 (-0.10, 0.44)
Haplotype 5
0 Reference Reference Reference
1 or 2 -0.10 (-0.33, 0.13) -0.17 (-0.38, 0.03) 0.02 (-0.10, 0.14)
Haplotype 6
0 Reference Reference Reference
1 or 2 0.07 (-0.09, 0.22) 0.07 (-0.15, 0.29) 0.06 (-0.07, 0.19)
Values are regression coefficients (95% confidence interval) and reflect the difference in standard deviation score of head circumference from 2nd trimester until
14 months of age for the different glucocorticoid haplotypes. SDS, gestational age adjusted standard deviation score; CI, confidence interval. Models are adjusted
for age at visit and gender.
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born with small size for gestational age (n = 55) was too
small for specific analyses focused on this group. Thus
generalizability is limited with respect to children born
preterm or with low birth weight.
Glucocorticoid receptor gene polymorphisms have
been identified that contribute to the variability in glu-
cocorticoid sensitivity. This sensitivity to glucocorticoids
is known to show a large interindividual variation [1].
Persons vary considerably in their response to both
endogenous and exogenous glucocorticoids. So it is
likely that these polymorphisms are to some extent
responsible for the variability in the sensitivity to gluco-
corticoids. Glucocorticoids are important regulators of
the immune system, inflammatory processes and many
other processes involved in fat and glucose metabolism.
Previous studies examined the potential role of gluco-
corticoids in the development of adult disease. Studies
in rats showed that activity of placental 11b-hydroxys-
teroid dehydrogenase type 2, which converts physiologi-
cal glucocorticoids to inactive products, correlates
positively with birth weight and negatively with placental
weight[30]. Similar findings were found in small preterm
infants [31]. Thus, fetuses with the greatest exposure to
growth-retarding maternal glucocorticoids have low
birth weight and high placental weight. In human stu-
dies, it is demonstrated that these fetuses might be at a
higher risk of subsequent hypertension [32]. In addition,
administration of low-dose dexamethasone to pregnant
rats not only reduces birth weight but also leads to high
blood pressure in young adult offspring [30]. Increased
exposure to cortisol in adults leads again to low birth
weight and postnatal growth acceleration, which are
well-known risk factors for cardiovascular disease, type
2 diabetes and obesity [2,3]. Therefore, these poly-
morphisms in the glucocorticoid receptor gene could, by
increasing glucocorticoid sensitivity in the fetus for
maternal glucocorticoids, lead to intrauterine growth
retardation and metabolic and cardiovascular diseases in
adulthood. Genetically established differences between
individuals in glucocortcoid sensitivity may also be asso-
ciated with these diseases.
The effect of glucocorticoids is mediated by the glu-
cocorticoid receptor. Rautanen et al reported a com-
mon glucocorticoid receptor haplotype to be
Table 6 Associations of glucocorticoid receptor haplotype with the risks of prenatal growth deceleration and
postnatal growth acceleration until 24 months of age
Prenatal growth deceleration
(95% CI)
Postnatal growth acceleration
(95% CI)
Glucocorticoid receptor haplotype (copies) Growth deceleration
(>-0.67 SDS)
Growth acceleration
(>0.67 SDS)
Haplotype 1
0 1.09 (0.84, 1.42) 1.07 (0.78, 1.48)
1 1.16 (0.95, 1.41) 1.11 (0.87, 1.42)
2 Reference Reference
Haplotype 2
0 Reference Reference
1 0.88 (0.73, 1.07) 0.99 (0.79, 1.26)
2 1.03 (0.68, 1.55) 1.20 (0.73, 1.97)
Haplotype 3
0 Reference Reference
1 1.17 (0.95, 1.43) 1.05 (0.82, 1.35)
2 0.90 (0.45, 1.84) 0.42 (0.13, 1.39)
Haplotype 4
0 Reference Reference
1 0.88 (0.71, 1.09) 0.97 (0.74, 1.25)
2 0.93 (0.47, 1.84) 0.80 (0.27, 2.39)
Haplotype 5
0 Reference Reference
1 or 2 0.96 (0.69, 1.34) 0.96 (0.65, 1.42)
Haplotype 6
0 Reference Reference
1 or 2 1.26 (0.86, 1.87) 1.28 (0.80, 2.07)
Values are odds ratios (95% confidence interval) and reflect the difference in risk of prenatal growth deceleration and postnatal growth acceleration until 24
months of age for the different glucocorticoid haplotypes compared to the reference group (-0.67 to 0.67 SDS change in weight SDS). SDS, gestational age
adjusted standard deviation score; CI, confidence interval. Models are adjusted for age at visit and gender.
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associated with short length and low weight at birth
and higher indices of HPAA function later in life [20].
In humans, the possible importance of glucocorticoid
sensitivity on fetal growth and HPA programming has
not been previously investigated. However, previous
studies have examined the associations of different
polymorphisms in the glucocorticoid receptor gene
and sensitivity to glucocorticoids. The results of these
studies are conflicting. A few studies report positive
associations between the N363S and BclI polymorph-
isms and hypersensitivity to glucocorticoids, as was
tested using a very low dose dexamethasone suppre-
sion test (0.25 mg) [9-11], while other studies found
no alterations of glucocorticoid sensitivity as tested
with a low dose (0.5 mg) dexamethasone suppresion
test [14]. The 23K variant of the R23K polymorphism
was associated with relative resistance to glucocorti-
coids [7,8]. No associations were found yet with the
TthIIII polymorphism [4,15]. These studies suggest
that genetically established differences in glucocort-
coid sensitivity are important for various growth,
development and health related outcomes. In addition,
it is known that environmental, dietary, and socioeco-
nomic factors also play an important role in determi-
nants of body composition and metabolic factors.
Reported associations of genetic variants with growth
outcomes depend on many additional factors, includ-
ing differences in characteristics between populations,
prevalence of the genotypes, and interactions. The dis-
tribution of the different glucocorticoid receptor hap-
lotypes within our study population was similar as in
the the general population [6,20]. Genotype and allele
frequencies were in Hardy Weinburg equilibrium (p >
0.01). Furthermore, the distribution of genotype fre-
quencies did not significantly differ between children
with and without postnatal growth data avialable.
Therefore we do not think that this would have intro-
duced major bias. Gene-environment and gene-gene
interactions might be important for glucocorticoid
receptor genotypes. Such studies require much more
power and need to be performed.
Conclusions
We hypothezised that genetic variants leading to
increased glucocorticoid sensitivity are associated with
fetal growth retardation and postnatal growth accelera-
tion. This hypothesis is based on previous observations
showing associations of cortisol levels and low birth
weight. Low birth weight and postnatal growth accelera-
tion are again associated with obesity and other meta-
bolic diseases. However, we did not find any consistent
effect on pre- and postnatal weight, length and head cir-
cumference between the different glucocorticoid recep-
tor haplotypes in our population-based study. Neither
did we find associations with prenatal growth decelera-
tion or postnatal growth acceleration.
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